By Discovering, Developing and Commercializing Global First-in-Class, Only-in-Class and/or Best-in-Class Therapies
Our clinical research and development center was established and commenced operation in Shanghai
We and Celgene established cooperation to develop and commercialize ATG-008 (onatasertib) in the APAC region
Our Group completed the Series A financing with an aggregate amount of approximately US$21 million
IND approval for the TORCH trial with respect to ATG-008 (onatasertib) was received in Taiwan
We and Karyopharm established cooperation to develop and commercialize four clinical-stage drug candidates, including ATG-010 (selinexor), in mainland China and certain other Asian countries and regions
IND approvals for the TORCH trial with respect to ATG-008 (onatasertib) were received in mainland China and South Korea
ATG-008 was selected into National Science and Technology Major Project
IND approval for the MARCH trial with respect to ATG-010 (selinexor) was received in mainland China
Our Group completed the Series B financing with an aggregate amount of approximately US$120 million
IND approval for the SEARCH trial with respect to ATG-010 (selinexor) was received in mainland China
Our Regulatory Affairs Center commenced operation in Beijing
Our Group won the championship of the 8th China Innovation & Entrepreneurship Competition
We and AstraZeneca established cooperation to develop, manufacture and commercialize ATG-017 worldwide
IND approval for the TEACH trial with respect to ATG-019 was received in Taiwan
ATG-010 was selected into National Science and Technology Major Project
Antengene was successfully listed on The Stock Exchange of Hong Kong Limited
Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor) in Mainland China for the Treatment of Myelodysplastic Syndrome
Antengene Submits NDA for ATG-010 (Selinexor) in South Korea for rrMM and rrDLBCL
Approval of IND Application in China for ATG-010 (Selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study
IND approval for the TOUCH trial with respect to ATG-010 (selinexor) was received in mainland China
Our licensed rights under the license agreement with Karyopharm were expanded to 17 APAC countries and regions
Our Group completed the Series C financing with an aggregate amount of approximately US$97 million
IND approval for the BUNCH trial with respect to ATG-008 (onatasertib) was received in mainland China
IND approval for the ERASER trial with respect to ATG-017 was received in Australia
Our Drug Discovery Center commenced operation in Shanghai
Our Manufacturing Center commenced operation in Zhejiang Province
Antengene Announces NDA for ATG-010?(Selinexor)?Granted Priority Review by China’s NMPA
Antengene Selected as a Constituent Stock of Nine Benchmark and Thematic Indexes Including the Hang Seng Composite Index
Antengene Included in the Shenzhen-Hong Kong Stock Connect
Antengene?Announces?NMPA?Approval?of?IND?Application?for?ATG-019?in?Patients?with?Advanced?Solid?Tumors?or?Non-Hodgkin’s?Lymphoma
Our clinical research and development center was established and commenced operation in Shanghai
We and Celgene established cooperation to develop and commercialize ATG-008 (onatasertib) in the APAC region
Our Group completed the Series A financing with an aggregate amount of approximately US$21 million
IND approval for the TORCH trial with respect to ATG-008 (onatasertib) was received in Taiwan
We and Karyopharm established cooperation to develop and commercialize four clinical-stage drug candidates, including ATG-010 (selinexor), in mainland China and certain other Asian countries and regions
IND approvals for the TORCH trial with respect to ATG-008 (onatasertib) were received in mainland China and South Korea
ATG-008 was selected into National Science and Technology Major Project
IND approval for the MARCH trial with respect to ATG-010 (selinexor) was received in mainland China
Our Group completed the Series B financing with an aggregate amount of approximately US$120 million
IND approval for the SEARCH trial with respect to ATG-010 (selinexor) was received in mainland China
Our Regulatory Affairs Center commenced operation in Beijing
Our Group won the championship of the 8th China Innovation & Entrepreneurship Competition
We and AstraZeneca established cooperation to develop, manufacture and commercialize ATG-017 worldwide
IND approval for the TEACH trial with respect to ATG-019 was received in Taiwan
ATG-010 was selected into National Science and Technology Major Project
Antengene was successfully listed on The Stock Exchange of Hong Kong Limited
Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor) in Mainland China for the Treatment of Myelodysplastic Syndrome
Antengene Submits NDA for ATG-010 (Selinexor) in South Korea for rrMM and rrDLBCL
Approval of IND Application in China for ATG-010 (Selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study
IND approval for the TOUCH trial with respect to ATG-010 (selinexor) was received in mainland China
Our licensed rights under the license agreement with Karyopharm were expanded to 17 APAC countries and regions
Our Group completed the Series C financing with an aggregate amount of approximately US$97 million
IND approval for the BUNCH trial with respect to ATG-008 (onatasertib) was received in mainland China
IND approval for the ERASER trial with respect to ATG-017 was received in Australia
Our Drug Discovery Center commenced operation in Shanghai
Our Manufacturing Center commenced operation in Zhejiang Province
Antengene Announces NDA for ATG-010?(Selinexor)?Granted Priority Review by China’s NMPA
Antengene Selected as a Constituent Stock of Nine Benchmark and Thematic Indexes Including the Hang Seng Composite Index
Antengene Included in the Shenzhen-Hong Kong Stock Connect
Antengene?Announces?NMPA?Approval?of?IND?Application?for?ATG-019?in?Patients?with?Advanced?Solid?Tumors?or?Non-Hodgkin’s?Lymphoma
